HMGCR and myeloid sarcoma: Our study reveals that HMGCR-mediated LDL-C lowering and HMGCR expression inhibition have causal relationships with a lower risk of RA, but none of the lipid traits and lipid-lowering targets were found to causally associate with the risk of SLE, MS, UC, and CD.